Attila A Seyhan

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers
    Attila A Seyhan
    Systems Biology, Global Biotherapeutics, Pfizer Inc, 200 CambridgePark Drive, Cambridge, MA 02140, USA
    Mol Biosyst 8:1553-70. 2012
  2. doi A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments
    Attila A Seyhan
    Systems Biology, Global Biotherapeutics, Pfizer Inc, 87 CambridgePark Drive, Cambridge, MA 02140, USA
    Mol Biosyst 7:1974-89. 2011
  3. doi RNAi: a potential new class of therapeutic for human genetic disease
    Attila A Seyhan
    Pfizer Inc, Translational Immunology, Inflammation and Immunology, 200 CambridgePark Drive, Cambridge, MA 02140, USA
    Hum Genet 130:583-605. 2011
  4. ncbi RNAi screening for the discovery of novel modulators of human disease
    Attila A Seyhan
    Systems Biology, Global Biotherapeutics, Pfizer Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA
    Curr Pharm Biotechnol 11:735-56. 2010

Detail Information

Publications4

  1. doi A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers
    Attila A Seyhan
    Systems Biology, Global Biotherapeutics, Pfizer Inc, 200 CambridgePark Drive, Cambridge, MA 02140, USA
    Mol Biosyst 8:1553-70. 2012
    ..Their use as patient or treatment selection biomarkers could make the application of anti-ErbB therapeutics more clinically effective...
  2. doi A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments
    Attila A Seyhan
    Systems Biology, Global Biotherapeutics, Pfizer Inc, 87 CambridgePark Drive, Cambridge, MA 02140, USA
    Mol Biosyst 7:1974-89. 2011
    ..Notably, our findings support a paclitaxel and neratinib phase III clinical trial in breast cancer patients...
  3. doi RNAi: a potential new class of therapeutic for human genetic disease
    Attila A Seyhan
    Pfizer Inc, Translational Immunology, Inflammation and Immunology, 200 CambridgePark Drive, Cambridge, MA 02140, USA
    Hum Genet 130:583-605. 2011
    ..In this review, progress and challenges in developing RNAi therapeutics for genetic diseases will be discussed...
  4. ncbi RNAi screening for the discovery of novel modulators of human disease
    Attila A Seyhan
    Systems Biology, Global Biotherapeutics, Pfizer Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA
    Curr Pharm Biotechnol 11:735-56. 2010
    ..Here, we review the use of RNAi in various screening formats, and examine the types of targets pursued for oncology and other disease indications...